{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:50Z","timestamp":1788897350858,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jconrel.2023.06.030","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T13:03:59Z","timestamp":1688043839000},"page":"274-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis"],"prefix":"10.1016","volume":"360","author":[{"given":"Bhuvanesh","family":"Yathavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Jedrzkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Subrahmanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah A.","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Ghandehari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.06.030_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2500\/aap.2019.40.4182","article-title":"A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis","volume":"40","author":"Palmer","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0020","doi-asserted-by":"crossref","first-page":"4602651","DOI":"10.1155\/2019\/4602651","article-title":"Nasal delivery devices: a comparative study on cadaver model","volume":"2019","author":"Moffa","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/alr.21172","article-title":"Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations","volume":"3","author":"Thomas","year":"2013","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121430","article-title":"Advances in controlled drug delivery to the sinonasal mucosa","volume":"282","author":"Schilling","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0035","first-page":"605","article-title":"Effect of budesonide added to large-volume, low-pressure saline sinus irrigation for chronic rhinosinusitis: a randomized clinical trial, JAMA","volume":"144","author":"Tait","year":"2018","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0040","first-page":"Doc09","article-title":"Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options","volume":"14","author":"Bachert","year":"2015","journal-title":"GMS Curr. Top. Otorhinolaryngol. Head Neck Surg."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0045","first-page":"CD011992","article-title":"Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis","volume":"4","author":"Head","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11882-012-0329-5","article-title":"Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis","volume":"13","author":"Howard","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2500\/ajra.2015.29.4223","article-title":"Oral corticosteroids in the management of chronic rhinosinusitis with and without nasal polyps: risks and benefits","volume":"29","author":"Poetker","year":"2015","journal-title":"Am. J. Rhinol. Allergy"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2018.06.010","article-title":"NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis","volume":"143","author":"Leopold","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0065","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/alr.21910","article-title":"Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis","volume":"7","author":"Manji","year":"2017","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020246","article-title":"Current perspective on nasal delivery Systems for Chronic Rhinosinusitis","volume":"13","author":"Tai","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/alr.21222","article-title":"The effect of head position on the distribution of topical nasal medication using the mucosal atomization device: a cadaver study","volume":"3","author":"Habib","year":"2013","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0080","doi-asserted-by":"crossref","first-page":"40249","DOI":"10.1038\/srep40249","article-title":"Sinonasal delivery of resveratrol via Mucoadhesive nanostructured microparticles in a nasal polyp mouse model","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ejps.2016.10.017","article-title":"Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - a platform for therapeutic delivery to mucosal sinus tissue","volume":"96","author":"Pandey","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jconrel.2020.10.062","article-title":"A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses","volume":"330","author":"Schilling","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jconrel.2011.03.001","article-title":"Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis","volume":"152","author":"Hofkens","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2015.03.027","article-title":"Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis","volume":"160","author":"Ren","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0105","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.1021\/acsnano.8b01249","article-title":"Micelle-forming dexamethasone prodrug attenuates nephritis in lupus-prone mice without apparent glucocorticoid side effects","volume":"12","author":"Jia","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/alr.22723","article-title":"Inflammation-driven vascular dysregulation in chronic rhinosinusitis","volume":"11","author":"Khurana","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0115","article-title":"Vascular permeability in chronic rhinosinusitis enhances accumulation and retention of nanoscale pegylated liposomes","volume":"38","author":"Khurana","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0120","doi-asserted-by":"crossref","first-page":"20304","DOI":"10.1021\/acsami.8b22693","article-title":"Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy","volume":"11","author":"Ren","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204709","article-title":"A synthetic glycosaminoglycan reduces sinonasal inflammation in a murine model of chronic rhinosinusitis","volume":"13","author":"Alt","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0130","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.otohns.2005.11.048","article-title":"Development of a murine model of chronic rhinosinusitis","volume":"134","author":"Lindsay","year":"2006","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0140","series-title":"Wilmington, DE. AstraZeneca","author":"Rhinocort [Package insert]","year":"1999"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0145","first-page":"1","article-title":"European position paper on Rhinosinusitis and Nasal Polyps 2012","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol. Suppl."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0090-9556(25)06497-9","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"J\u00f6nsson","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0155","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14656566.2016.1183648","article-title":"Budesonide for the treatment of ulcerative colitis","volume":"17","author":"Abdalla","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0165","series-title":"North American Colonies. January 2008\u2013December 2012","author":"BALB\/C Mouse Biochemistry","year":"2023"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0170","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3109\/13693786.2010.485582","article-title":"An inhalation model of airway allergic response to inhalation of environmental Aspergillus fumigatus conidia in sensitized BALB\/c mice","volume":"48","author":"Hoselton","year":"2010","journal-title":"Med. Mycol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0091-6749(96)80194-1","article-title":"Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma","volume":"98","author":"Spahn","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.V53.4.633.633","article-title":"Effects of in vivo prednisone on in vitro eosinophil and neutrophil adherence and chemotaxis","volume":"53","author":"Clark","year":"1979","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10928-006-9013-5","article-title":"Pharmacokinetic\/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide","volume":"33","author":"Stark","year":"2006","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI107591","article-title":"Human lymphocyte subpopulations. Effect of corticosteroids","volume":"53","author":"Yu","year":"1974","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0195","series-title":"North American Colonies. January 2008\u2013December 2012","author":"BALB\/C Mouse Hematology","year":"2023"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0200","doi-asserted-by":"crossref","first-page":"30439","DOI":"10.1038\/srep30439","article-title":"Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model","volume":"6","author":"Wong","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/10611860600648429","article-title":"Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD","volume":"14","author":"Jubeh","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0210","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.11140","article-title":"Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes","volume":"48","author":"Metselaar","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0215","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jconrel.2020.10.061","article-title":"Meta-analysis of global and high throughput public gene array data for robust vascular gene expression discovery in chronic rhinosinusitis: implications in controlled release","volume":"330","author":"Khurana","year":"2020","journal-title":"J. Control. Release."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0225","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijpharm.2011.02.062","article-title":"Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide","volume":"416","author":"Hofkens","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-015-0579-0","article-title":"Immune mechanisms of chronic rhinosinusitis","volume":"16","author":"Hulse","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0235","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ard.2003.009944","article-title":"Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis","volume":"63","author":"Metselaar","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0240","first-page":"39","article-title":"Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis","volume":"7","author":"Iborra","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40268-018-0253-9","article-title":"Efficacy and safety of budesonide in the treatment of eosinophilic esophagitis: updated systematic review and Meta-analysis of randomized and non-randomized studies","volume":"18","author":"Rawla","year":"2018","journal-title":"Drugs R D"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0250","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-018-05800-6","article-title":"Resolution of chronic inflammatory disease: universal and tissue-specific concepts","volume":"9","author":"Schett","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0255","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/brain\/awg176","article-title":"Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis","author":"Schmidt","year":"2003","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0260","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar3089","article-title":"Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis","volume":"12","author":"Anderson","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0265","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: Quintiles Prize Lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.biomaterials.2014.10.030","article-title":"Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases","volume":"37","author":"Bartneck","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.06.030_bb0275","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ijpharm.2011.03.025","article-title":"Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis","volume":"416","author":"van den Hoven","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0280","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/01926230701595300","article-title":"Society of toxicologic pathology position paper: organ weight recommendations for toxicology studies","volume":"35","author":"Sellers","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0285","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/ar2889","article-title":"Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment","volume":"11","author":"Rauchhaus","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2023.06.030_bb0290","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0091-6749(80)90153-0","article-title":"Long-term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics","volume":"65","author":"Chiang","year":"1980","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:47:43Z","timestamp":1759164463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923004030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"alternative-id":["S0168365923004030"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}